Vanda raises cash in anticipation of tasimelteon approval

Vanda Pharmaceuticals is taking advantage of a spike in its stock price to sell 4.68 million shares following recent US FDA acceptance of its new drug application (NDA) for tasimelteon and the regulator's decision to grant priority review for the sleep disorder drug.

Vanda Pharmaceuticals is taking advantage of a spike in its stock price to sell 4.68 million shares following recent US FDA acceptance of its new drug application (NDA) for tasimelteon and the regulator's decision to grant priority review for the sleep disorder drug.

Washington, D.C.-based Vanda priced the 7 August offering at $11.14 per share, mirroring the company's 6 August closing stock price, for net proceeds of $48.3 million. The stock sale could...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By 

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By 

Vyepti revenues rise by nearly 70% in the first quarter.

More from Therapy Areas